Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | NR1H2 | P55055 | 3/20 | 0.40 |
| ▸ | NR1H3 | Q13133 | 3/20 | 0.40 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | WNT3 | P56703 | 2/20 | 0.38 |
| ▸ | SFRP1 | Q8N474 | 2/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22012470 | 0.95 | NR1H2 (0.40) | KMT2AMEN1NPC1NR1H2NR1H3 | |
| SCHEMBL25033880 | 0.90 | KMT2A (0.46) | KMT2AMEN1NPC1ALDH1A1NR1H2 | |
| SCHEMBL22012883 | 0.84 | STS (0.43) | KMT2AMEN1NR1H2NR1H3RIPK1 | |
| SCHEMBL20680936 | 0.82 | CHRNB2 (0.43) | — | |
| SCHEMBL21962692 | 0.79 | GPR119 (0.49) | KMT2AMEN1NPC1ALDH1A1NR1H2 | |
| SCHEMBL21611379 | 0.77 | RIPK1 (0.52) | KMT2AMEN1NPC1ALDH1A1RIPK1 | |
| SCHEMBL22772314 | 0.77 | RIPK1 (0.52) | KMT2AMEN1NPC1ALDH1A1RIPK1 | |
| SCHEMBL16409394 | 0.77 | GPR119 (0.53) | KMT2AMEN1NR1H2NR1H3RIPK1 | |
| SCHEMBL16409297 | 0.76 | CA2 (0.51) | KMT2AMEN1NR1H2NR1H3RIPK1 | |
| SCHEMBL18406188 | 0.75 | NPC1 (0.63) | KMT2AMEN1NPC1ALDH1A1RIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230051589-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2023-02-16 | — | — | US | disclosed |
| WO-2020102576-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS INFLAMMASOME RESEARCH, INC. (US) | 2020-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230051589-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NLRP1, NLRP3, NOD1 | KMT2A 4465/4885MEN1 3277/4885NPC1 73/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.